复方丹参片是目前治疗冠心病的基本中成药,广泛应用于临床,市场容量大,全国有140多个厂家生产。但丹参酮Ⅱ_A检出阴性率高。卫生部多年药品质量抽检,曝光的劣药中复方丹参片最多,许多厂家生产复方丹参片的批文被取消。目前复方丹参片工艺鱼龙混珠,制剂有效成分参差不一,药效与质量难以保证。因此,复方丹参片的质量及标准亟待提高。 Compound Danshen Tablets is the basic Chinese patent medicine for the treatment of coronary heart disease. It is widely used in clinical practice and has a large market capacity. There are more than 140 manufacturers in China. However, the negative rate of detection of tanshinone II_A was high. The Ministry of Health has sampled the quality of pharmaceuticals for many years, and the exposure of the compound is the most common compound Danshen tablet. Many manufacturers have eliminated the approval of compound Danshen tablets. At present, compound Danshen tablet technology is a mixed fish, the active ingredients of the preparation are mixed, and the efficacy and quality of the preparation are difficult to guarantee. Therefore, the quality and standards of compound Danshen tablets need to be improved.